<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03703063</url>
  </required_header>
  <id_info>
    <org_study_id>CRP17118</org_study_id>
    <nct_id>NCT03703063</nct_id>
  </id_info>
  <brief_title>Alternative Neoadjuvant Chemotherapy in Resectable and Borderline Resectable Pancreatic Cancer</brief_title>
  <official_title>Alternating Neoadjuvant Gemcitabine-Nab-Paclitaxel and Nanoliposomal Irinotecan (Nal-IRI) With 5-Fluorouracil and Folinic Acid (Leucovorin) Regimens in Resectable and Borderline Resectable Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Benaroya Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Benaroya Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Using alternative neoadjuvant gemcitabine-nab-paclitaxel and nal-IRI with 5-Fluorouracil&#xD;
      (5FU) and folinic acid (Leucovorin) regimens of localized cancer, we hope to ensure exposure&#xD;
      of the cancer to a broader array of potentially active agents. Also, potentially improves&#xD;
      patient tolerance and minimizes significant drug toxicity that could impair delivery of all&#xD;
      treatment elements. Furthermore, it may enable prediction of superior to inferior treatment&#xD;
      outcomes at an earlier point in the disease progress.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This research study is a Phase Ib clinical trial. It will assess the Safety, tolerability,&#xD;
      and feasibility of gemcitabine-nab paclitaxel alternating with nal-IRI/5FU/leucovorin&#xD;
      (NAPOLI) in de novo resectable and borderline resectable pancreatic cancer.&#xD;
&#xD;
      Subjects must have a newly diagnosed resectable or borderline resectable pancreatic ductal&#xD;
      cancer and meet all inclusion/exclusion criteria.&#xD;
&#xD;
      Treatment consists of 4 week treatment cycles. Nab-paclitaxel and gemcitabine will be&#xD;
      administered on days 1,8, and 15 with NAPOLI will be administered on days 1 and 15.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 17, 2018</start_date>
  <completion_date type="Anticipated">September 17, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 17, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Resectable patients And Borderline resectable patients</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment safety as assessed by CTCAE v4.03</measure>
    <time_frame>An average of 1 year</time_frame>
    <description>Toxicities are evaluated according to CTCAE v4.03</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 years</time_frame>
    <description>OS is defined as the time between the date of enrollment and the date of death (whatever the cause).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>5 years</time_frame>
    <description>PFS is defined as the time between the date of enrollment and the date of the first radiological and/or pathological progression. Progression is assessed by investigator according to RECIST v1.1 criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>An average of 1 year</time_frame>
    <description>Response rate will be assessed per RECIST v1.1 criteria and CA19-9 over the entire treatment period.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Pancreatic Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Resectable patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gemcitabine and Nab-Paclitaxel Participants received albumin-bound paclitaxel 125 mg/m^2 followed by gemcitabine 1000 mg/m^2 by intravenous infusion (IV) on Days 1, 8 and 15 of each 28 day cycle. Followed by nal-IRI (ONIVYDE®) 70 mg/m^2 followed by leucovorin 400 mg/m^2 followed by 5FU 2400 mg/m^2 on days 1, 15 of the 28 day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Borderline resectable patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gemcitabine and Nab-Paclitaxel Participants received albumin-bound paclitaxel 125 mg/m^2 followed by gemcitabine 1000 mg/m^2 by intravenous infusion (IV) on Days 1, 8 and 15 of each 28 day cycle. Followed by nal-IRI (ONIVYDE®) 70 mg/m^2 followed by leucovorin 400 mg/m^2 followed by 5FU 2400 mg/m^2 on days 1, 15 of the 28 day cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Administered by intravenous infusion over 30 minutes.</description>
    <arm_group_label>Borderline resectable patients</arm_group_label>
    <arm_group_label>Resectable patients</arm_group_label>
    <other_name>Gemzar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nab paclitaxel</intervention_name>
    <description>Administered by intravenous infusion over 30-40 minutes.</description>
    <arm_group_label>Borderline resectable patients</arm_group_label>
    <arm_group_label>Resectable patients</arm_group_label>
    <other_name>Abraxane</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Onivyde</intervention_name>
    <description>Administered by intravenous infusion over 90 minutes.</description>
    <arm_group_label>Borderline resectable patients</arm_group_label>
    <arm_group_label>Resectable patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leucovorin</intervention_name>
    <description>Administered by intravenous infusion over 30 minutes.</description>
    <arm_group_label>Borderline resectable patients</arm_group_label>
    <arm_group_label>Resectable patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-fu</intervention_name>
    <description>Administered by intravenous infusion over 46 hours.</description>
    <arm_group_label>Borderline resectable patients</arm_group_label>
    <arm_group_label>Resectable patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Pathologically proven resectable or borderline resectable pancreatic cancer per&#xD;
             current NCCN criteria&#xD;
             (http://www.nccn.org/professionals/physician_gls/f_guidelines.asp).&#xD;
&#xD;
          2. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0/1.&#xD;
&#xD;
          3. Adequate bone marrow reserves as evidenced by:&#xD;
&#xD;
               -  absolute neutrophil count (ANC) ≥1,500 cells/μl without the use of hematopoietic&#xD;
                  growth factors; and&#xD;
&#xD;
               -  Platelet count ≥100,000 cells/μl; and&#xD;
&#xD;
               -  Hemoglobin ≥9 g/dL (blood transfusions are permitted for patients with hemoglobin&#xD;
                  levels below 9 g/dL).&#xD;
&#xD;
          4. Adequate hepatic function as evidenced by:&#xD;
&#xD;
               -  Serum total bilirubin within normal range for the institution (biliary drainage&#xD;
                  is allowed for biliary obstruction); and&#xD;
&#xD;
               -  aspartate aminotransferase (AST) and alanine aminotransferase (ALT)&#xD;
&#xD;
                    -  2.5 x upper limit of normal (ULN) (≤5 x ULN is acceptable if liver&#xD;
                       metastases are present).&#xD;
&#xD;
          5. Adequate renal function as evidenced by a serum creatinine ≤1.5 x ULN.&#xD;
&#xD;
          6. At least 18 years of age.&#xD;
&#xD;
          7. Women of child-bearing potential (defined as a sexually mature woman who (1) has not&#xD;
             undergone hysterectomy [the surgical removal of the uterus] or bilateral oophorectomy&#xD;
             [the surgical removal of both ovaries] or (2) has not been naturally postmenopausal&#xD;
             for at least 24 consecutive months [i.e., has had menses at any time during the&#xD;
             preceding 24 consecutive months]) must: Either commit to true abstinence from&#xD;
             heterosexual contact (which must be reviewed on a monthly basis), or agree to use, and&#xD;
             be able to comply with, effective contraception without interruption for 28 days prior&#xD;
             to starting study medications (including dose interruptions) and for 3 months after&#xD;
             last dose of study medication and Have a negative pregnancy test result at screening&#xD;
             and agree to ongoing pregnancy testing at the Investigator's discretion during the&#xD;
             course of the study. This applies even if the subject practices true abstinence from&#xD;
             heterosexual contact.&#xD;
&#xD;
          8. Male subjects must practice true abstinence or agree to use a condom during sexual&#xD;
             contact with a female of childbearing potential or a pregnant female while on&#xD;
             treatment (including during dose interruptions) with study medications and for 3&#xD;
             months following the last dose of study medication, even if he has undergone a&#xD;
             successful vasectomy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prior therapy for pancreatic cancer (e.g., attempted surgery, chemotherapy, radiation&#xD;
             therapy).&#xD;
&#xD;
          2. Any contraindication to curative surgery.&#xD;
&#xD;
          3. History of any second malignancy in the last 5 years except in-situ cancer or basal or&#xD;
             squamous cell skin cancer. Subjects with history of other malignancies are eligible if&#xD;
             they have been continuously disease free for at least 5 years.&#xD;
&#xD;
          4. Severe arterial thromboembolic events (myocardial infarction, unstable angina&#xD;
             pectoris, stroke) less than 6 months before study participation.&#xD;
&#xD;
          5. New York Heart Association (NYHA) Class III or IV congestive heart failure,&#xD;
             ventricular arrhythmias or uncontrolled blood pressure.&#xD;
&#xD;
          6. Active infection or an unexplained fever &gt;38.5°C during screening visit or on the&#xD;
             first scheduled day of dosing in each cycle which, in the Investigator's opinion,&#xD;
             might compromise the subject's participation in the trial or affect the study outcome.&#xD;
             Subjects with tumor fever may be enrolled at the discretion of the Investigator.&#xD;
&#xD;
          7. Known hypersensitivity to any of the components of nal-IRI, other liposomal products,&#xD;
             fluoropyrimidines or leucovorin.&#xD;
&#xD;
          8. Neuropathy &gt; grade 1.&#xD;
&#xD;
          9. Investigational therapy administered within 4 weeks, or within a time interval less&#xD;
             than at least 5 half-lives of the investigational agent, whichever is longer, prior to&#xD;
             the first scheduled day of dosing in this study.&#xD;
&#xD;
         10. Any other medical or social condition deemed by the Investigator to be likely to&#xD;
             interfere with a subject's ability to sign informed consent, cooperate and/or&#xD;
             participate in the study in any way, or interfere with the interpretation of the&#xD;
             results.&#xD;
&#xD;
         11. Inability or unwillingness to provide written informed consent.&#xD;
&#xD;
         12. Patients who are not appropriate candidates for participation in this clinical study&#xD;
             for any other reason as determined by the investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vincent J Picozzi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Virginia mason medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vincent J Picozzi, MD</last_name>
    <phone>206-223-6193</phone>
    <email>Vincent.Picozzi@virginiamason.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Virginia mason medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vincent J Picozzi, MD</last_name>
      <phone>206-223-6193</phone>
      <email>Vincent.Picozzi@virginiamason.org</email>
    </contact>
    <investigator>
      <last_name>Vincent Picozzi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>October 8, 2018</study_first_submitted>
  <study_first_submitted_qc>October 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 11, 2018</study_first_posted>
  <last_update_submitted>January 25, 2021</last_update_submitted>
  <last_update_submitted_qc>January 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pancreatic cancer</keyword>
  <keyword>nal-IRI</keyword>
  <keyword>NAPOLI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

